Ismail Kola - UCB SA EVP

UCBJY Stock  USD 58.22  1.22  2.14%   

EVP

Dr. Ismail Kola was Executive Vice President, New Medicines Head and Chief Scientific Officer and Member of the Executive Committee of UCB S.A. since November 2009. He joined the Company in November 2009. He holds a Doctorate in Philosophy in Medicine from the University of Cape Town, South Africa. He also holds a BS from the University of South Africa UNISA and a Bachelors degree from Rhodes University. He joined the Company from Schering Plough Corporation where he was Senior Vice President, Discovery Research and Early Clinical Research Experimental Medicine, ScheringPlough Research Institute, the pharmaceutical research arm of ScheringPlough Corporationrationration, and Chief Scientific Officer, Schering Plough Corporationrationration. He came to ScheringPlough from Merck, where he was Senior Vice President and Site Head, Basic Research. He also chaired Merck Antibacterial and Antifungal Worldwide Business Strategy Team. Prior to that, he was Vice President, Research, and Global Head, Genomics Science and Biotechnology, with Pharmacia Corporationrationration. Prior to his move to Industry, Ismail was Professor of Human Molecular Genetics, Monash University Medical School and Director of the Research Center for Functional Genomics and Human Disease. He was at Monash for approximately 15 years. He holds Adjunct Professorships of Medicine at Washington University, St Louis, Missouri, United States, and Monash University Medical School, Melbourne, Australia a Foreign Adjunct Professorship at The Karolinska Institute, Stockholm, Sweden and is a William Pitt Fellow at Pembroke College, Cambridge University, United Kingdom. He is Member of the Board of Athersys Inc., Biotie Therapies, and Astex Pharmaceuticals. since 2009.
Age 59
Tenure 15 years
Professional MarksPh.D
Phone32 2 559 99 99
Webhttps://www.ucb.com
Kola holds a Doctorate in Philosophy in Medicine from the University of Cape Town, South Africa. He also holds a BS from the University of South Africa UNISA and a Bachelors degree from Rhodes University. He joined the Company from Schering Plough Corporationration where he was Senior Vice President, Discovery Research and Early Clinical Research & Experimental Medicine, ScheringPlough Research Institute, the pharmaceutical research arm of ScheringPlough Corporationration, and Chief Scientific Officer, Schering Plough Corporationration. He came to ScheringPlough from Merck, where he was Senior Vice President and Site Head, Basic Research. He also chaired Merck Antibacterial and Antifungal Worldwide Business Strategy Team. Prior to that, he was Vice President, Research, and Global Head, Genomics Science and Biotechnology, with Pharmacia Corporationration

UCB SA Management Efficiency

The company has return on total asset (ROA) of 0.0468 % which means that it generated a profit of $0.0468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1069 %, meaning that it generated $0.1069 on every $100 dollars invested by stockholders. UCB SA's management efficiency ratios could be used to measure how well UCB SA manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 1.97 B in total debt with debt to equity ratio (D/E) of 0.34, which is about average as compared to similar companies. UCB SA ADR has a current ratio of 1.1, suggesting that it may not have the ability to pay its financial obligations in time and when they become due. Debt can assist UCB SA until it has trouble settling it off, either with new capital or with free cash flow. So, UCB SA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like UCB SA ADR sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for UCB to invest in growth at high rates of return. When we think about UCB SA's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 4 records

EVP Age

Neil StahlRegeneron Pharmaceuticals
61
Mads ThomsenNovo Nordisk AS
58
Stuart ArbuckleVertex Pharmaceuticals
52
Jakob RiisNovo Nordisk AS
49
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company was incorporated in 1925 and is headquartered in Brussels, Belgium. UCB S operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 8600 people. UCB SA ADR [UCBJY] is a Pink Sheet which is traded between independent brokers as part of over-the-counter (OTC) trading.

Management Performance

UCB SA ADR Leadership Team

Elected by the shareholders, the UCB SA's board of directors comprises two types of representatives: UCB SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of UCB. The board's role is to monitor UCB SA's management team and ensure that shareholders' interests are well served. UCB SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, UCB SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Pascale Richetta, Executive Vice President Bone Patient Value Unit Head, Member of the Executive Committee
Detlef Thielgen, CFO and Executive VP
Kay Davies, Independent Director
Dirk Teuwen, VP Corporate Societal Responsibility
Anna Richo, Executive VP and General Counsel
Viviane Monges, Independent Non-Executive Director
Gerhard Mayr, Non-Executive Chairman of the Board
Cyril Janssen, Director
Caroline Vancoillie, Chief Functions
Cedric Rijckevorsel, Director
JeanChristophe Tellier, Chairman of the Executive Committee, CEO
Arnoud Calesberg, Non-Executive Director
Mark McDade, COO and Executive VP
Xavier Michel, Vice President and Secretary General
Dhavalkumar Patel, Executive Vice President Chief Scientific Officer, Member of the Executive Committee
Bharat Tewarie, Executive Vice President Chief Marketing Officer
Roch Doliveux, Chairman of the Executive Committee, CEO, Executive Director
Norman Ornstein, Non-Executive Independent Director
Jeff Wren, Executive Vice President Neurology – Patient Value Unit Head
JeanPierre Kinet, Non-Executive Independent Director
Antje Witte, VP of Investor Relations
Alice Dautry, Independent Director
Sandrine CFA, Ex CFO
Harriet Edelman, Non-Executive Independent Director
Ulf Wiinberg, Independent Director
William Silbey, Exec Counsel
Thomas McKillop, Non-Executive Independent Director
Charl Zyl, Executive Vice President Head of Patient Value Operations, Member of the Executive Committee
France Nivelle, VP Global Communication
Fabrice Enderlin, Executive Vice President - Human Resources & Communication, Member of the Executive Committee
Pierre Gurdjian, Independent Director
Ismail Kola, Chief Scientific Officer, Head of New Medicines Patient Value Unit and Executive VP
Emmanuel Caeymaex, Executive Vice President Immunology - Patient Value Unit Head
Evelyn Bergendal, Non-Executive Vice Chairwoman of the Board
Iris LoewFriedrich, Executive Vice President Chief Medical Officer
CharlesAntoine Janssen, Non-Executive Director
Pr LowFriedrich, Chief VP
Kirsten LundJurgensen, Ex Solutions
Albrecht Graeve, Non-Executive Independent Director
JeanLuc Fleurial, Executive Vice President Chief Talent Officer, Member of the Executive Committee
Alexander Moscho, Executive Vice President Chief Strategy Officer, Member of the Executive Committee

UCB Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is UCB SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UCB SA ADR. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in inflation.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for UCB Pink Sheet analysis

When running UCB SA's price analysis, check to measure UCB SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UCB SA is operating at the current time. Most of UCB SA's value examination focuses on studying past and present price action to predict the probability of UCB SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UCB SA's price. Additionally, you may evaluate how the addition of UCB SA to your portfolios can decrease your overall portfolio volatility.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Bonds Directory
Find actively traded corporate debentures issued by US companies
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Please note, there is a significant difference between UCB SA's value and its price as these two are different measures arrived at by different means. Investors typically determine if UCB SA is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UCB SA's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.